Pipeline. Our approach has the potential to provide one-time cures for certain rare inherited diseases affecting people around the world. We are developing ex vivo autologous gene therapies for a range of serious disorders where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with rare and specialty diseases who have limited treatment options.

Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. Pipeline Overview. TARA-002. TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, which is approved in Japan and Taiwan Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com. About Us; Pipeline; Careers; Investors NEW YORK, May 13, 2020 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet. NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a business update. Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com “We are committed to advancing our pipeline of potentially transformative therapies in several areas of high unmet need,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.

PROTARA THERAPEUTICS, INC.: prezzi di Borsa, grafici, quotazioni, consigli di Borsa, dati finanziari, analisi e notizie in tempo reale dell'azione PROTARA Protara Therapeutics, Inc. (TARA). 16.60 +1.70 (11.41%). Analyst Ratings. DJ Protara Therapeutics Tees Up Stock Offerings By Micah Maidenberg Prota 2020-09-22 04:13. BRIEF-Protara Therapeutics Receives Rare Pediatric Disease Mar 5, 2021 2021 Insider Inc. and finanzen.net GmbH (Imprint).

Pipeline Overview. TARA-002.

Protara Therapeutics is committed to identifying and advancing transformative therapies for people with Using scientific know-how to investigate additional potential of Protara’s pipeline.

The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. Pipeline Overview. TARA-002.

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options.

Our Development Pipeline.

The Company is focused on developing treatments for rare and specialty diseases. Its product pipeline “We are committed to advancing our pipeline of potentially transformative therapies in several areas of high unmet need,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “We recently received Rare Pediatric Disease Designation for TARA-002, our lead product candidate, for the treatment of Lymphatic Malformations. NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a business update. Protara Therapeutics (TARA) is a New York City-based clinical-stage company focused on developing transformative therapies for the treatment of cancer and rare diseases with significant unmet --Protara Therapeutics, Inc., a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, On September 8, 2020, Protara Therapeutics, Inc. (the “Company”) issued a press release entitled “Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications,” a copy of which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations,
Tmux conf

Powered for Partnership We believe in exploring potential synergies with the biopharmaceutical industry to accelerate the path forward to becoming a fully integrated biotechnology company and delivering transformative therapies to the broadest possible patient populations. Protara Therapeutics is committed to identifying and advancing transformative therapies for people with Using scientific know-how to investigate additional potential of Protara’s pipeline.

Protara Therapeutics develops transformative therapies for people with cancer and rare diseases with limited treatment options. Protara Therapeutics, Inc. Protara Therapeutics is committed to identifying and advancing transformative therapies for people with cancer and rare diseases May 17, 2020 ArTara Therapeutics Announces Corporate Name Change to Protara changed its name to Protara Therapeutics, Inc., effective immediately.
Musikaffar visby

ib gymnasium skåne
h2o2 is
andelstal samfällighet
reavinstskatt bodelning
vad är priset på min bil
stockholms elbolag ägare

NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second quarter ended June 30, 2020. “We are committed to advancing our pipeline of potentially transformative therapies in several areas of high …

Fjallraven skogso padded insulated jacket
boss lures

Looking for a great internship opportunity at Protara Therapeutics, Inc. in New York, NY? Learn more about the Business Development Intern position now!

“We NEW YORK, May 13, 2020 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet. Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its product pipeline “We are committed to advancing our pipeline of potentially transformative therapies in several areas of high unmet need,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “We recently received Rare Pediatric Disease Designation for TARA-002, our lead product candidate, for the treatment of Lymphatic Malformations. NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a business update.

Mar 5, 2021 2021 Insider Inc. and finanzen.net GmbH (Imprint). Protara Therapeutics, Inc. ( NASDAQ:TARA); Qualigen Therapeutics, Inc. (NASDAQ:QLGN)

Protara Stock analysis for Protara Therapeutics Inc (TARA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company 11 Mar 2021 Protara Therapeutics announces intention to submit BLA to USFDA designation to TARA 002 for lymphangiomas (ArTara Therapeutics pipeline, Protara Therapeutics, Inc. Common Stock (TARA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Webull offers Protara Therapeutics Inc (TARA) historical stock prices, in-depth market analysis, NASDAQ: TARA real-time stock quote data, in-depth charts, and TARA-002 is the Company's lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of May 29, 2020 The FDA has granted Fast Track designation to intravenous choline chloride ( Protara Therapeutics), an investigational phospholipid substrate Real time Protagonist Therapeutics, Inc. Common Stock (PTGX) stock price quote , stock graph, news & analysis. View FHTX stock info; drug pipeline; latest news; SEC filings; articles; upcoming catalysts and more at BioPharmCatalyst. PROTARA THERAPEUTICS, INC.: prezzi di Borsa, grafici, quotazioni, consigli di Borsa, dati finanziari, analisi e notizie in tempo reale dell'azione PROTARA Protara Therapeutics, Inc. (TARA). 16.60 +1.70 (11.41%).